Table 2.
Hematology and platelet function testing at week 8 by treatment group.
| Week 8 | Both delayed N = 14 | ISMN N = 15 | Cilostazol N = 13 | Both immediate N = 14 | Cilostazol vs. none (2 + 3 vs. 1 + 4*) | ISMN vs. none (1 + 3 vs. 2 + 4*) | Cil + ISMN vs. one or other (3 + 4 vs. 1 + 2) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Full blood count, adjusted for baseline | Week 3 (4*) | Week 8 (4) | Week 8 (1) | Week 8 (2) | Week 8 (3) | MD (95% CI) | p-value | MD (95% CI) | p-value | MD (95% CI) | p-value |
| Hemoglobin (g/L), mean (SD) | 133.0 (12.2) | 136.2 (13.5) | 146.9 (12.0) | 130.8 (9.5) | 137.1 (14.6) | −3.7 (−8.4, 1.0) | 0.12 | −1.0 (−6.9, 4.9) | 0.73 | −2.4 (−6.8, 2.1) | 0.30 |
| Platelet count (x109/L), mean (SD) | 260.3 (47.1) | 258.4 (56.1) | 238.6 (45.5) | 289.5 (61.4) | 284.3 (57.8) | 35.7 (2.8, 68.7) | 0.033 | 3.9 (−32.4, 40.2) | 0.83 | −7.4 (−36.8, 21.9) | 0.62 |
| Platelet function, adjusted for baseline | |||||||||||
| Unstimulated median fluorescence, mean (SD) | 87.0 (29.0) | 80.4 (29.1) | 86.1 (29.0) | 75.9 (27.3) | 83.7 (33.8) | −2.9 (−15.1, 9.3) | 0.64 | −8.2 (−20.7, 4.2) | 0.20 | 7.5 (−4.0, 19.0) | 0.20 |
| AA median fluorescence, mean (SD) | 741.0 (395.0) | 775.4 (474.4) | 675.2 (364.1) | 636.4 (272.4) | 679.6 (376.6) | −83.6 (−256.5, 89.4) | 0.34 | −14.1 (−192.5, 164.2) | 0.88 | 109.7 (−54.0, 273.5) | 0.19 |
| ADP median fluorescence, mean (SD) | 519.3 (234.5) | 502.1 (242.8) | 454.9 (238.8) | 518.9 (179.5) | 451.7 (176.5) | −1.3 (−77.6, 75.0) | 0.97 | −0.5 (−80.1, 79.1) | 0.99 | 11.9 (−60.2, 84.1) | 0.75 |
AA, arachidonic acid (aspirin test); ADP, adenosine diphosphate (clopidogrel test); CI, confidence intervals; ISMN, isosorbide mononitrate; MD, mean difference; SD, standard deviation.